KRSeoul National University Hospital, Seoul · South Korea
GLP1R variant common in East Asians tied to stronger blood sugar response in a Korean study
A Seoul National University Hospital team linked the R131Q variant of the GLP-1 receptor, carried by about four in ten East Asians, to bigger HbA1c falls on GLP-1 drugs. Weight loss did not differ, and the clinical data are observational.
Illustration by Peptide Global, not a picture of the place in the story.
The short of itA Seoul study linked the GLP1R R131Q variant, carried by about four in ten East Asians, to larger HbA1c falls on GLP-1 drugs and a stronger receptor signal in the lab.
A GLP1R variant carried by about four in ten East Asians was linked to larger blood sugar falls in Korean patients taking GLP-1 drugs for type 2 diabetes. Seoul National University Hospital announced the work on 16 November, combining patient records, a 20-year cohort, clamp tests and lab studies of the receptor. Each extra copy of the variant came with a bigger drop in HbA1c, while weight loss did not differ. The team calls the clinical part observational and plans randomized trials before anyone uses it to guide treatment.
Who ran the study and what they tested
The work was led by Professor Kwak Soo-heon of the endocrinology department at Seoul National University Hospital, with Professor Kim Jong-il and Dr Lee Hyun-suk of the Genomic Medicine Institute at Seoul National University College of Medicine, Professor Park Kyong-soo of Konkuk University Medical Center and researchers at the Mayo Clinic in the United States, Korea Biomedical Review reported. The hospital's announcement did not name a journal in the coverage. The target was R131Q, also catalogued as rs3765467, a change in the gene for the GLP-1 receptor. It is common in East Asian populations and very rare in Europeans, where its allele frequency is below 0.3 percent. Earlier research had tied it to slightly lower odds of type 2 diabetes, but the mechanism was unclear.
That gap matters for a class of drugs whose effects vary widely between patients. GLP-1 receptor agonists such as dulaglutide, liraglutide and semaglutide lower blood sugar and body weight, yet doctors have no routine marker that predicts who will respond strongly. The Seoul group therefore looked at the variant from four angles. They checked treatment results in hospital records, followed beta-cell function in a long population cohort, measured insulin release in volunteers under controlled glucose levels, and tested the receptor itself in cells and in pancreatic islets donated by surgical patients. A finding that holds up across all four methods carries more weight than a single association, though it still falls short of proof from a controlled trial.
What the GLP1R variant did to HbA1c
The clinical arm drew on 177 people with type 2 diabetes who had used GLP-1 drugs for at least six months at four hospitals: the main Seoul National University Hospital, its Bundang branch, Gachon University Gil Medical Center and SMG-SNU Boramae Medical Center. Of these, 119 carried no copy of the variant, 51 carried one and seven carried two. On average each added copy meant HbA1c fell a further 0.53 percentage points. Patients without the variant saw a fall of 0.57 points, compared with 1.05 points for one copy and 1.30 points for two. Most patients, about 80 percent, were on dulaglutide, so the results say most about that drug and less about semaglutide or tirzepatide.
On average each added copy meant HbA1c fell a further 0.53 percentage points.
The share of patients who reached an HbA1c of 7 percent or lower after six months rose with each copy too: 8.4 percent with none, 22 percent with one and 43 percent with two. Weight loss, by contrast, looked about the same across the three groups. That split suggests the GLP1R variant works on the insulin side of the drug's action rather than on appetite. The small number of people with two copies means that group's figures carry wide uncertainty, and the analysis was observational, so other differences between patients could explain part of the gap. The researchers have said as much, which is why they describe their next step as randomized testing rather than a change in prescribing.
| Copies of R131Q | Patients | Average HbA1c fall | Reached HbA1c of 7 percent or lower | Beta-cell index fall over 20 years in the cohort |
|---|---|---|---|---|
| None | 119 | 0.57 points | 8.4 percent | 37 percent |
| One | 51 | 1.05 points | 22 percent | 35 percent |
| Two | 7 | 1.30 points | 43 percent | 30 percent |
A stronger signal inside the beta cell
The cohort arm used the Ansan and Ansung study of the Korean Genome and Epidemiology Study, which followed 6,373 people without diabetes for 20 years. Over that time the disposition index, which scores beta-cell output while adjusting for how sensitive the body is to insulin, dropped from baseline by 37 percent in non-carriers, by 35 percent with a single copy and by 30 percent with a double copy. In cell experiments the variant receptor produced a stronger cyclic AMP signal, the messenger that drives insulin secretion, and bound less to beta-arrestin 2, a protein that damps receptor activity. Peak cyclic AMP was 1.43 times the normal receptor's level with natural GLP-1 and 1.28 times with semaglutide.
The team read this as biased signalling, where one pathway is favoured over another, and classed R131Q as a gain-of-function variant. Human tests pointed the same way. In clamp studies at the Mayo Clinic with 17 people without diabetes, carriers tended to release more insulin after liraglutide. In islets from 21 surgical patients without diabetes at the Seoul hospital, insulin output after exendin-4 rose with the number of variant copies. "These findings give us a genetic clue to why blood sugar falls more in some patients than in others taking the same drug," Kwak said, adding that they may help explain earlier reports that East Asian patients respond better to these drugs.
What it could mean for care in Korea
For Korean doctors the study offers a possible reason behind a pattern seen in clinics, not a new test to order. GLP-1 drugs are widely used in Korea, where regulators recently widened the label of Mounjaro for heart risk and pediatric diabetes. Interest in weight loss use runs high among young adults, as a recent national survey showed. If the GLP1R variant does predict a stronger glucose response, it could one day help choose between drug classes or set expectations at the start of treatment. Because the variant is so common in East Asia, any such use would matter far more for patients in Korea, Japan and China than for patients in Europe.
Park, the Konkuk University endocrinologist, said several lines of evidence linked the variant to preserved beta-cell function and a stronger drug response. He added that "because the clinical findings came from observational research, we plan to validate them in randomized clinical trials." That plan sets the timeline. Until a trial assigns treatment and compares carriers with non-carriers, the result stays a strong hypothesis. Readers can follow the hospital's statement through Korea Biomedical Review, which published the detailed study figures. The study also adds to wider evidence that drugs designed mainly on European trial data can behave differently in Asian populations, a point clinicians have also raised about body mass thresholds drawn from Western trials.
Conclusion
The GLP1R variant R131Q, carried by about four in ten East Asians, was tied to deeper HbA1c falls on GLP-1 drugs, to slower loss of beta-cell function over 20 years and to a stronger receptor signal in the lab. Weight loss did not change with the variant. The evidence is observational and mostly from dulaglutide users, so the next thing to watch is the randomized trial the Seoul team has promised and the journal publication of the full data.
Why it matters in South Korea
The variant is common in Korea and rare in Europe, so it may help explain reports that East Asian patients respond better to GLP-1 drugs. GLP-1 use is growing fast in Korea, but the finding is observational and does not change prescribing yet.
What to watch
The randomized trials the team plans, and publication of the full paper with the journal named.
Sources
Spotted a wrong figure? Tell the desk; we fix errors under our corrections policy.
Peptide Global reports news about medicines and markets. Nothing here is medical or investment advice.